Lisata Therapeutics, Inc., a clinical-stage biopharmaceutical company, is focused on developing and commercializing cellular therapies to reverse disease and/or promote regeneration of damaged tissue. The company is headquartered in Basking Ridge, New Jersey.
| Revenue (TTM) | 170,000 |
| Gross Profit (TTM) | 170,000 |
| EBITDA | $-17.20M |
| Operating Margin | -10179.00% |
| Return on Equity | -91.40% |
| Return on Assets | -50.30% |
| Revenue/Share (TTM) | $0.02 |
| Book Value | $1.20 |
| Price-to-Book | 2.79 |
| Price-to-Sales (TTM) | 171.95 |
| EV/Revenue | 50.49 |
| EV/EBITDA | 0.82 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -90.00% |
| Shares Outstanding | $9.11M |
| Float | $7.20M |
| % Insiders | 20.89% |
| % Institutions | 11.43% |
Volatility is currently contracting
SAN DIEGO, June 26, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating Lisata Therapeutics, Inc. (NASDAQ: LSTA) on behalf of investors who suffered losses and whether those losses may be recoverable under federal securities laws.
Bala Cynwyd, Pennsylvania--(Newsfile Corp. - June 15, 2026) - Law office of Brodsky & Smith announces that it is investigating potential claims against the Board of Directors of Lisata Therapeutics, Inc. ("Lisata Therapeutics" or the "Company") (NASDAQ - LSTA) for possible breaches of fiduciary duty and other violations of federal and state law in connection with the sale of the Company to Kuva Labs, Inc. ("Kuva") for $4.00 per share in cash plus two non-tradeable contingent value rights (CVRs), payable as follows: (1) $1.00 per share, in cash, within 12 months of the date on which rights to certepetide in the Greater China region revert to Lisata from Qilu Pharmaceutical; and (2) $1.00 per share, in cash, upon the filing of an NDA or similar registration document by Kuva for approval to commercialize certepetide in any indication in any jurisdiction. The investigation concerns whether the Lisata Therapeutics Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether the deal consideration provides fair value to the Company's shareholders.
Lisata Therapeutics Inc (NASDAQ:LSTA, FRA:8NE) has agreed to be acquired by privately held Kuva Labs Inc. for $4 per share in cash, plus a contingent value right worth up to an additional $3.00 per share tied to drug development milestones.
Lisata stockholders to receive $4.00 per share in cash at closing, plus one non-tradeable contingent value right, which represents the contractual right to receive two contingent cash payments of up to an aggregate of $3.00 per share, subject to achievement of specified milestones
Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.
